Limits...
Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Gomes FV, Guimarães FS, Grace AA - Int. J. Neuropsychopharmacol. (2014)

Bottom Line: Evidence from studies in animals has indicated that a combination of repeated pubertal cannabinoid administration with either neonatal prefrontocortical lesion, isolation rearing, or chronic NMDA receptor antagonism administration induces enhanced schizophrenia-like behavioral disruptions.Adult rats were tested for attentional set-shifting task and locomotor response to amphetamine, which was compared with in vivo recording from ventral tegmental area (VTA) dopamine (DA) neurons.Taken together, the present results indicate that the impact of cannabinoids during puberty/adolescence on schizophrenia models is more complex than may be predicted.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil (Drs Gomes and Guimarães); Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Gomes and Guimarães); Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, A210 Langley Hall, Pittsburgh, PA 15260 (Dr Grace). gomesfv@usp.br.

Show MeSH

Related in: MedlinePlus

Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4368886&req=5

Figure 1: Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).

Mentions: As adults, the animals were submitted to the behavioral (PD85–PD100) and electrophysiological tests (PD100–PD125; Figure 1). The WIN dose and the experimental design were based on previous studies (Schneider and Koch, 2002, 20032005, 2007; Schneider et al., 2005; Schneider et al., 2008; Du and Grace, 2013; Zimmerman et al., 2013). All experiments were performed with investigators blinded to treatment.


Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Gomes FV, Guimarães FS, Grace AA - Int. J. Neuropsychopharmacol. (2014)

Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4368886&req=5

Figure 1: Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
Mentions: As adults, the animals were submitted to the behavioral (PD85–PD100) and electrophysiological tests (PD100–PD125; Figure 1). The WIN dose and the experimental design were based on previous studies (Schneider and Koch, 2002, 20032005, 2007; Schneider et al., 2005; Schneider et al., 2008; Du and Grace, 2013; Zimmerman et al., 2013). All experiments were performed with investigators blinded to treatment.

Bottom Line: Evidence from studies in animals has indicated that a combination of repeated pubertal cannabinoid administration with either neonatal prefrontocortical lesion, isolation rearing, or chronic NMDA receptor antagonism administration induces enhanced schizophrenia-like behavioral disruptions.Adult rats were tested for attentional set-shifting task and locomotor response to amphetamine, which was compared with in vivo recording from ventral tegmental area (VTA) dopamine (DA) neurons.Taken together, the present results indicate that the impact of cannabinoids during puberty/adolescence on schizophrenia models is more complex than may be predicted.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil (Drs Gomes and Guimarães); Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Gomes and Guimarães); Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, A210 Langley Hall, Pittsburgh, PA 15260 (Dr Grace). gomesfv@usp.br.

Show MeSH
Related in: MedlinePlus